|
Back to 2015 Annual Meeting Program
The Elevated Pretreatment Mean Platelet Volume As a Predictor of Poor Overall Survival in Pancreatic Cancer Patients
Basem Azab*1, Ariful Alam1, Masood a. Shariff1, Wolf K. Von Waagner1, Alina Bhat2, Osama Souied2, Laura Klingbeil1, Antonio I. Picon1, Scott W. Bloom1
1Surgery, Staten Island University Hospital, Staten Island, NY; 2Internal medicine, staten island university hospital, Staten Island, NY
Background: Previous studies demonstrated the significance of elevated platelet lymphocyte ratio (PLR) as a predictor of poor survival in pancreatic cancer patients. Our aim in this study was to investigate the predicting values of the pretreatment PLR and the mean platelet volume (MPV).
Methods: An observational study of prospectively maintained database of 338 consecutive pancreatic cancer patients was performed. Patients were included if they have available complete blood count before any treatment modality (surgery and chemotherapy). Survival status was obtained from our cancer registry and social security death index. Patients were divided according to the median values of their PLR and MPV.
Results: Total of 193 patients were qualified for the study. There were 35 patients who underwent pancreatectomy. According to Kaplan Meier survival analysis (Log-Rank and Berslow), the patients with higher MPV had poor survival compared to those with lower MPV (figure 1). However, PLR was not a significant predictor.
Conclusion: The elevated pretreatment MPV (MPV > 8.7) is a significant predictor of poor survival in pancreatic cancer patients. This finding concurs with previously reported association between pancreatic cancer and up-regulation of the platelet derived growth factor receptor (PDGFR).
Figure 1: Overall survival among pancreatic cancer patients according to their mean platelet volume (MPV).
Back to 2015 Annual Meeting Program
|
